ArticleEJHaem2023

Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria.

Anna Gaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.